A5036761306- Prostate Cancer Treatment and Research
- Bladder and Urothelial Cancer Treatments
- Prostate Cancer Diagnosis and Treatment
- Renal cell carcinoma treatment
- Radiopharmaceutical Chemistry and Applications
- Cancer, Lipids, and Metabolism
- Cancer Immunotherapy and Biomarkers
- Urinary and Genital Oncology Studies
- Cancer Genomics and Diagnostics
- Renal and related cancers
- Urological Disorders and Treatments
- Multiple Myeloma Research and Treatments
- Testicular diseases and treatments
- Urologic and reproductive health conditions
- Hormonal and reproductive studies
- Cardiac, Anesthesia and Surgical Outcomes
- Lymphoma Diagnosis and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Intestinal and Peritoneal Adhesions
- Medical Imaging and Pathology Studies
- Hematological disorders and diagnostics
- Tracheal and airway disorders
- Cancer Treatment and Pharmacology
- Pediatric Urology and Nephrology Studies
- Travel-related health issues
Dana-Farber Cancer Institute
2013-2025
Government Medical College
2025
Università Cattolica del Sacro Cuore
2024
Harvard University
2010-2024
Dana-Farber Brigham Cancer Center
2023
Brigham and Women's Hospital
2013-2023
Roche (Switzerland)
2020
Bristol-Myers Squibb (Germany)
2020
Novartis (Switzerland)
2020
GlaxoSmithKline (France)
2020
Loss of the tumor suppressor phosphatase and tensin homolog (PTEN) occurs frequently in prostate cancers. Preclinical evidence suggests that activation PI3K/AKT signaling through loss PTEN can result resistance to hormonal treatment cancer.To explore antitumor activity abiraterone acetate (abiraterone) castration-resistant cancer (CRPC) patients with without protein expression.We retrospectively identified who had received hormone-sensitive (HSPC) and/or CRPC tissue available for...
Translocation renal cell carcinoma (tRCC) is a poorly characterized subtype of kidney cancer driven by MiT/TFE gene fusions. Here, we define the landmarks tRCC through an integrative analysis 152 patients with identified across genomic, clinical trial, and retrospective cohorts. Most tRCCs harbor few somatic alterations apart from fusions homozygous deletions at chromosome 9p21.3 (19.2% cases). Transcriptionally, display heightened NRF2-driven antioxidant response that associated resistance...
Abstract Advances in therapy recent years have led investigators to challenge the dogma that multiple myeloma (MM) is incurable. We assessed overall (OS) and progression-free survival (PFS) of young patients ( ≤ 50 years) with MM compared outcomes follicular lymphoma (FL), diffuse large B-cell (DLBCL), Hodgkin (HL). All newly diagnosed n = 212), FL 168), DLBCL 195), HL 233) between 1 January 2005 31 December 2015 were included. Observed vs. expected was summarized by standardized mortality...
To determine the association between race/ethnicity and perioperative outcomes in individuals undergoing major oncologic nononcologic surgical procedures United States.Prior work has shown that there are significant racial/ethnic disparities after several types of cardiac, general, vascular, orthopedic, cancer procedures. However, recent evidence suggests attenuation these differences, particularly at academic institutions.We utilized American College Surgeons National Surgical Quality...
Several immune checkpoint inhibitors (ICIs) are approved for use in patients with metastatic renal cell carcinoma (mRCC), but the efficacy and safety of ICI rechallenge mRCC is unknown.To evaluate mRCC.This multicenter, retrospective cohort study included consecutive from 9 institutions US who received at least 2 separate lines (ICI-1, ICI-2) between January 2012 December 2019.Receipt an (anticytotoxic T-lymphocyte-associated protein 4, anti-programmed death 1, or ligand 1), alone...
Abstract The current definition of plasma cell leukemia (PCL)— ≥ 20% circulating cells (CPCs) on peripheral smear and count 2 × 10 9 /L—may be too stringent. We reviewed outcomes 176 multiple myeloma (MM) patients diagnosed between 1971 2016, who had CPCs detectable at diagnosis, to determine whether a lower threshold could used diagnose PCL. Median overall survival (mOS) was 1.1 years (95% CI 0.8–1.4) similar with < 5% ( n = 54, mOS 1.4 [0.7–2.0]), 5–19% 63, [0.7–1.4]), 59, [0.7–1.5], p...
No AccessJournal of UrologyAdult Urology1 Apr 2013Robot-Assisted Versus Open Radical Prostatectomy: The Differential Effect Regionalization, Procedure Volume and Operative Approach Jesse D. Sammon, Pierre I. Karakiewicz, Maxine Sun, Shyam Sukumar, Praful Ravi, Khurshid R. Ghani, Marco Bianchi, James O. Peabody, Shahrokh F. Shariat, Paul Perrotte, Jim C. Hu, Mani Menon, Quoc-Dien Trinh SammonJesse Sammon Vattikuti Urology Institute, Henry Ford Health System, Detroit, Michigan Equal study...
Introduction: This is a timely update of incidence and mortality for renal cell carcinoma (RCC) in the United States.Methods: Relying on Surveillance, Epidemiology, End Results (SEER) database, we computed age-adjusted incidence, rates 5-year cancer-specific survival (CSS) patients with histologically confirmed kidney cancer between 1975 2009. Long-term (1975–2009) short-term (2000–2009) trends were examined by joinpoint analysis, quantified using annual percent change (APC). The reported...
Abstract We studied 190 patients with smoldering multiple myeloma (SMM) at our institution between 1973 and 2014. Evolving change in monoclonal protein level (eMP) was defined as ⩾10% increase serum (M) and/or immunoglobulin (Ig) (M/Ig) within the first 6 months of diagnosis (only if M-protein ⩾3 g/dl) ⩾25% M/Ig 12 months, a minimum required 0.5 g/dl 500 mg/dl Ig. hemoglobin (eHb) ⩾0.5 decrease diagnosis. A total 134 (70.5%) progressed to MM over median follow-up 10.4 years. On multivariable...
The optimal management approach to advanced or metastatic renal cell cancer of the clear type continues rapidly evolve. Risk stratification patients into favorable-, intermediate-, and poor-risk categories is now routinely performed. In selected individuals with low-volume indolent disease, active surveillance may be an appropriate option. Cytoreductive nephrectomy and/or surgical metastasectomy also considered for after evaluation by a multidisciplinary tumor board. Systemic frontline...
Prostate cancer (PCa) is marked by disparities in clinical outcomes race, ethnicity, and age. Equitable enrollment trials fundamental to promoting health equity.To evaluate the inclusion of racial ethnic minority groups older adults across PCa trials.MEDLINE, Embase, ClinicalTrials.gov were searched identify primary trial reports from each database's inception through February 2021. Global incidence age subgroups US population-based acquired Burden Disease Surveillance, Epidemiology, End...
We sought to compare outcomes between neoadjuvant therapy with a novel hormonal agent (NHA) prior radical prostatectomy (neo-RP) and up-front (RP) in patients high-risk prostate cancer (HRPC).HRPC treated on 3 trials of NHA followed by RP formed the neo-RP cohort (112). The group (259) comprised an observational HRPC undergoing without 2010-2016 at our institution who met key eligibility criteria for (ie ≥3 positive biopsy cores Gleason ≥4+3=7). Inverse probability treatment weighting (IPTW)...
PURPOSE We sought to evaluate the prognostic impact of prostate-specific antigen (PSA) at 6 months after completion radiotherapy (RT) in patients treated with RT alone, plus short-term (st; 3-6 months), and long-term (lt; 24-36 months) androgen-deprivation therapy (ADT). PATIENTS AND METHODS Individual patient data were obtained from 16 randomized trials evaluating ± ADT for localized prostate cancer (PCa) between 1987 2011. The lowest PSA recorded within was identified categorized as <...
The aim of this study is to investigate the incidence and mortality emergency department (ED) visits in United States attributed acute pancreatitis (AP) quantify predictors admission mortality.Using nationwide ED sample, all between 2006 2009 for AP were extracted. Multivariable analyses fitted prediction mortality.A weighted sample 1,224,121 patient with was captured. Of those, 75.4% resulted 0.7% died. Between 2009, increased from 9.9 10.6 per 10,000 person-years. Patients more likely be...